Promising combo for Triple-Negative breast cancer stalls as trial ends early
NCT ID NCT03838367
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested a drug called leronlimab combined with the chemotherapy carboplatin in people with a specific type of advanced triple-negative breast cancer (CCR5-positive). The goal was to find a safe dose and see if it could slow cancer growth. However, the study was stopped early after enrolling only 10 participants, so we have very little information about how well it worked or its risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
leronlimab (a monoclonal antibody) combined with carboplatin (a chemotherapy drug)
What this could lead to
If it had worked, this combination might have offered a new treatment option for a hard-to-treat breast cancer type.
What could go wrong
The trial was terminated early with only 10 participants, so results are very limited. It is unclear if the combination is safe or effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CD07 Investigational Site
Chicago, Illinois, 60611, United States
-
Quest Clinical Research
San Francisco, California, 94115, United States